Breadcrumb

David Takeda, M.D., Ph.D.

David Takeda, M.D., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Laboratory of Genitourinary Cancer Pathogenesis

RESEARCH SUMMARY

Dr. Takeda’s research is focused on understanding the role of epigenetic reprogramming in disease progression by combining genomic and epigenomic profiling of patient samples with functional studies in model systems. Current areas of investigation include identifying noncoding drivers of castration-resistance in prostate cancer, interrogating regulatory elements using unbiased proteomic and genetic approaches, and therapeutic targeting of oncogenic transcriptional programs in genitourinary cancers.

Areas of Expertise

Epigenetics
Functional Genomics
Chromatin

Publications

Selected Recent Publications

A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer

Takeda DY*, Spisak S*, Seo JH, Bell C, O’Conner E, Korthauer K, Ribli D, Csabai I, Solymosi N, Szallasi Z, Stillman DR, Cejas P, Qiu X, Long H, Tisza V, Nuzzo PV, Rohanizadegan M, Pomerantz MM, Hahn WC, Freedman ML. (*co-first author)
Cell. 174(2): 422-432, 2018. [ Journal Article ]

Prostate cancer reactivates developmental epigenomic programs during metastatic progression

Pomerantz MM, Qiu X, Zhu Y, Takeda DY, Pan W, Baca SC, Gusev A, Korthauer KD, Severson TM, Ha G, Viswanathan SR, Seo JH, Nguyen HM, Zhang B, Pasaniuc B, Giambartolomei C, Alaiwi SA, Bell CA, O'Connor EP, Chabot MS, Stillman DR, Lis R, Font-Tello A, Li L, Cejas P, Bergman AM, Sanders J, van der Poel HG, Gayther SA, Lawrenson K, Fonseca MA, Reddy J, Corona RI, Martovetsky G, Egan B, Choueiri T, Ellis L, Garraway IP, Lee GM, Corey E, Long HW, Zwart W, Freedman ML
Nature Genetics. 52(8): 790-799, 2020. [ Journal Article ]

Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer

Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, Cejas P, Lim K, He M, Sheahan A, Nassar A, Berchuck JE, Brown L, Nguyen HM, Coleman IM, Kaipainen A, De Sarkar N, Nelson PS, Morrissey C, Korthauer K, Pomerantz MM, Ellis L, Pasaniuc B, Lawrenson K, Kelly K, Zoubeidi A, Hahn WC, Beltran H, Long HW, Brown M, Corey E, Freedman ML.
Nature Communications. Mar 30;12(1): 1979, 2021. [ Journal Article ]

Mutational processes shape the landscape of TP53 mutations in human cancer

Giacomelli AO, Yang X, Linter RE, McFarland JM, Duby M, Kim J, Howard TP, Takeda DY, Ly SH, Kim E, Gannon HS, Hurhula B, Sharpe T, Goodale A, Fritchman B, Steelman S, Vazquez F, Tsherniak A, Aguirre AJ, Doench JG, Piccioni F, Roberts CW, Meyerson M, Getz G, Johannessen CM, Root DE, Hahn WC.
Nature Genetics. 50(10): 1381-1387, 2018. [ Journal Article ]

The androgen receptor is extensively reprogrammed in human prostate tumorigenesis

Pomerantz MM*, Li F*, Takeda DY*, Lenci R, Chonkar A, Chabot M, Cejas P, Vazquez F, Cook J, Shivdasani RA, Bowden M, Lis R, Hahn WC, Kantoff PW, Brown M, Loda M, Long HW, Freedman ML. (*co-first author)
Nature Genetics. 47(11): 1346-1351, 2015. [ Journal Article ]

Job Vacancies

There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.

Team

Postdoctoral Fellow (CRTA)
Aleksandra Adamovich , Ph.D.
Postdoctoral Fellow (Visiting)
Shin-Ai Lee, Ph.D.
Postbaccalaureate Fellow (CRTA)
Clara Seo
Postbaccalaureate Fellow (CRTA)
Matt Kipp
Postbaccalaureate Fellow (CRTA)
Rachel Xiang

News

Newest Lasker Scholars Ready to Make Their Mark

Congratulations to the investigators who recently joined the ranks of the Lasker Clinical Research Scholars Program, NIH’s collaborative effort with the Albert and Mary Lasker Foundation to nurture the next generation of clinical researchers, including David Takeda, whose research focuses on treatment-resistant prostate cancer. Read More

Reprogramming Cancer

David Takeda, M.D., Ph.D. is laying the groundwork for a bold new approach to cancer therapy. He believes that manipulating epigenetics could also provide a powerful new pathway for combatting the disease. Instead of thinking about cancer in terms of the mutated genes that drive their abnormal growth and division, perhaps we can reprogram the cell’s state,” he explains. “A cancer cell is a cell that is no longer, say, a skin cell. It’s now a new type of cell that can grow unrestricted. Maybe we can epigenetically reprogram the cell and give it a set of instructions so that it turns into something else — something that you can treat. Read More